COMMUNIQUÉS West-GlobeNewswire

-
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
15/02/2024 -
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
15/02/2024 -
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
15/02/2024 -
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
15/02/2024 -
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
15/02/2024 -
10 Barrel Brewing Co. Announces Official Beer Sponsorship of the Natural Selection Tour
15/02/2024 -
LifeMD to Participate in Upcoming Investor Conferences and Webinar
15/02/2024 -
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
15/02/2024 -
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
15/02/2024 -
Extendicare Announces February 2024 Dividend of C$0.04 per Share
15/02/2024 -
Vaccinex, Inc. Announces Reverse Stock Split
15/02/2024 -
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
15/02/2024 -
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
15/02/2024 -
Communiqué de presse : Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente
15/02/2024 -
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
15/02/2024 -
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15/02/2024 -
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15/02/2024 -
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15/02/2024 -
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
15/02/2024
Pages